Summary
Immunotherapies using tumor-targeting T cells—e.g. TILs or T cells engineered with CARs or TCRs—have revolutionized cancer treatment, particularly for blood cancers like leukemia and lymphoma. However, their success against solid tumors has been limited. A major barrier is...